• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Recordati S.p.A. - Product Pipeline Review - 2012 Product Image

Recordati S.p.A. - Product Pipeline Review - 2012

  • ID: 2136013
  • May 2012
  • 113 pages
  • Global Markets Direct

Recordati S.p.A. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Recordati S.p.A. - Product Pipeline Review - 2012” provides data on the Recordati S.p.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Recordati S.p.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from Recordati S.p.A. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Recordati S.p.A. - Brief Recordati S.p.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Recordati S.p.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination READ MORE >



List of Tables
List of Figures
Recordati S.p.A. Snapshot
Recordati S.p.A. Overview
Key Information
Key Facts
Recordati S.p.A. – Research and Development Overview
Key Therapeutic Areas
Recordati S.p.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Recordati S.p.A. – Pipeline Products Glance
Recordati S.p.A. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Recordati S.p.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Recordati S.p.A. – Drug Profiles
Carbaglu
Product Description
Mechanism of Action
R&D Progress
Cystadrops
Product Description
Mechanism of Action
R&D Progress
Normosang
Product Description
Mechanism of Action
R&D Progress
NX-1207
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Phase II - Trial Details
Product Description
Mechanism of Action
R&D Progress
REC 1819
Product Description
Mechanism of Action
R&D Progress
Stanate
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Licensing and Collaboration
Phase II - Trial Details
Recordati S.p.A. – Pipeline Analysis
Recordati S.p.A. – Pipeline Products by Therapeutic Class
Recordati S.p.A. – Pipeline Products By Target
Recordati S.p.A. – Pipeline Products by Route of Administration
Recordati S.p.A. – Pipeline Products By Mechanism of Action
Recordati S.p.A. – Recent Pipeline Updates
Recordati S.p.A. - Dormant Projects
Recordati S.p.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recordati S.p.A., Recent Developments
Recordati S.p.A.- Press Release
Nov 20, 2009: EMEA/CHMP Adopts A Positive Opinion For Silodosin
Sep 21, 2009: Recordati Reports Phase III Data Demonstrated Pitavastatin Is Non-Inferior To Atorvastatin And Simvastatin
Sep 21, 2009: Recordati Reports Pitavastatin Demonstrates No Significant Drug-To-Drug Interaction When Administered With CYP3A4 Inhibitors
Jul 29, 2009: Recordati Signs Agreement With Nycomed For Co-Marketing Of Silodosin In Italy
Jan 08, 2009: Application Filed For Dysuria Treatment KMD-3213 In China
Financial Deals Landscape
Recordati S.p.A., Deals Summary
Recordati S.p.A., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Recordati Acquires Rights To Procto-Glyvenol From Novartis
Orphan Europe Acquires Cystadane And Related Product Rights From Jazz Pharma
Recordati Acquires Marketing Rights For Corifeo In Germany From UCB
Recordati Acquires Trademarks And Marketing Authorizations From Roche
Recordati Acquires Marketing Rights Of Zanidip From Napp Pharma
Recordati Acquires Branded Pharma Business From Merckle
Partnerships
Recordati Signs An Agreement With Amdipharm
Orphan Europe Enters Into Licensing Agreement With CMIC
Recordati Enters Into Licensing Agreement With Watson Pharma
Recordati Enters Into Agreement With Kowa Pharma
Meda Extends Its Collaboration Agreement With Recordati
Meda Extends Its Agreement With Recordati
Orphan Europe Enters Into Distribution Agreement With Teva Pharma
Peptimmune Enters Into Collaboration Agreement With Orphan Europe
Recordati Signs Agreement With Osmotica Pharma
ASINEX Enters Into Collaboration With Recordati
Recordati Sign An Agreement With Eurand Pharma
Recordati Enters Into An Agreement With Almirall
Recordati Enters Into Collaboration With Lifecycle Pharma
Licensing Agreements
Recordati Enters Into Licensing Agreement With Zambon
Recordati Enters Into A License Agreement With Nycomed
Recordati Enters Into A Licensing Agreement With Pharmathen
Recordati Enters Into Licensing Agreement With Merck For Cardicor
Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin
Recordati Enters Into Licensing Agreement With Nymox Pharma For NX-1207
Recordati Enters Into Licensing Agreement With Laboratorios Del Dr. Esteve
Recordati Enters Into A License Agreement With Pharmaplan
Recordati Enters Into A Licensing Agreement With Amdipharm
Recordati Enters Into A Licensing Agreement With Almirall For Silodosin
Orion Enters Into Agreement With Recordati
Recordati Enters Into Licensing Agreement With The Menarini Group
Recordati Extends Its Agreement With Berlin-Chemie
Orphan Europe Enters Into Licensing Agreement With Rare Disease Therapeutics For Cystadane
Recordati Enters Into Licensing Agreement With Ony For Infasurf
Labopharm Enters Into License And Distribution Agreement With Recordati
Recordati Enters Into Licensing Agreement With Lavipharm Labs
Recordati Entered Into Licensing Agreement With InfaCare
Kissei Pharma Enters Into Licensing Agreement With Recordati
Recordati Signs Licensing Agreement With Angelini
Recordati Enters Into Licensing Agreement With Grupo Uriach
Debt Offering
Recordati Raises $18 Million In Private Placement
Recordati Raises $40 Million In Private Placement
Recordati Raises $32 Million In Private Placement
Recordati Raises $9 Million In Private Placement
Asset Transactions
Labopharm Reacquires Marketing Rights To Tramadol XL From Recordati
Recordati Sells Its Pharma Chemicals Plant In Spain
Acquisition
Recordati Completes Acquisition Of Frik Ilac From Is Private Equity For $130 Million
Recordati Acquires ArtMed International
Recordati Acquires HERBACOS-BOFARMA
Recordati Acquires Yeni Ilac
Tecnimede Acquires Majority Stake In Atlantic Pharma
Recordati Acquires Orphan Europe
Recordati Acquires Jaba Farmaceutica
Recordati Sells Minority Stake In Polfa Kutno To IVAX
Recordati Acquires Minority Stake In Polfa Kutno
Recordati Sells Sophartex To BTT Finances
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Recordati S.p.A., Key Information
Recordati S.p.A., Key Facts
Recordati S.p.A. – Pipeline by Indication, 2012
Recordati S.p.A. – Pipeline by Stage of Development, 2012
Recordati S.p.A. – Monotherapy Products in Pipeline, 2012
Recordati S.p.A. – Phase III, 2012
Recordati S.p.A. – Phase II, 2012
Recordati S.p.A. – Phase I, 2012
Recordati S.p.A. – Pipeline By Therapeutic Class, 2012
Recordati S.p.A. - Pipeline By Target, 2012
Recordati S.p.A. – Pipeline By Route of Administration, 2012
Recordati S.p.A. – Pipeline Products By Mechanism of Action, 2012
Recordati S.p.A. – Recent Pipeline Updates, 2012
Recordati S.p.A. - Dormant Developmental Projects,2012
Recordati S.p.A., Subsidiaries
Recordati S.p.A., Deals Summary
Recordati Acquires Rights To Procto-Glyvenol From Novartis
Orphan Europe Acquires Cystadane And Related Product Rights From Jazz Pharma
Recordati Acquires Marketing Rights For Corifeo In Germany From UCB
Recordati Acquires Trademarks And Marketing Authorizations From Roche
Recordati Acquires Marketing Rights Of Zanidip From Napp Pharma
Recordati Acquires Branded Pharma Business From Merckle
Recordati Signs An Agreement With Amdipharm
Orphan Europe Enters Into Licensing Agreement With CMIC
Recordati Enters Into Licensing Agreement With Watson Pharma
Recordati Enters Into Agreement With Kowa Pharma
Meda Extends Its Collaboration Agreement With Recordati
Meda Extends Its Agreement With Recordati
Orphan Europe Enters Into Distribution Agreement With Teva Pharma
Peptimmune Enters Into Collaboration Agreement With Orphan Europe
Recordati Signs Agreement With Osmotica Pharma
ASINEX Enters Into Collaboration With Recordati
Recordati Sign An Agreement With Eurand Pharma
Recordati Enters Into An Agreement With Almirall
Recordati Enters Into Collaboration With Lifecycle Pharma
Recordati Enters Into Licensing Agreement With Zambon
Recordati Enters Into A License Agreement With Nycomed
Recordati Enters Into A Licensing Agreement With Pharmathen
Recordati Enters Into Licensing Agreement With Merck For Cardicor
Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin
Recordati Enters Into Licensing Agreement With Nymox Pharma For NX-1207
Recordati Enters Into Licensing Agreement With Laboratorios Del Dr. Esteve
Recordati Enters Into A License Agreement With Pharmaplan
Recordati Enters Into A Licensing Agreement With Amdipharm
Recordati Enters Into A Licensing Agreement With Almirall For Silodosin
Orion Enters Into Agreement With Recordati
Recordati Enters Into Licensing Agreement With The Menarini Group
Recordati Extends Its Agreement With Berlin-Chemie
Orphan Europe Enters Into Licensing Agreement With Rare Disease Therapeutics For Cystadane
Recordati Enters Into Licensing Agreement With Ony For Infasurf
Labopharm Enters Into License And Distribution Agreement With Recordati
Recordati Enters Into Licensing Agreement With Lavipharm Labs
Recordati Entered Into Licensing Agreement With InfaCare
Kissei Pharma Enters Into Licensing Agreement With Recordati
Recordati Signs Licensing Agreement With Angelini
Recordati Enters Into Licensing Agreement With Grupo Uriach
Recordati Raises $18 Million In Private Placement
Recordati Raises $40 Million In Private Placement
Recordati Raises $32 Million In Private Placement
Recordati Raises $9 Million In Private Placement
Labopharm Reacquires Marketing Rights To Tramadol XL From Recordati
Recordati Sells Its Pharma Chemicals Plant In Spain
Recordati Completes Acquisition Of Frik Ilac From Is Private Equity For $130 Million
Recordati Acquires ArtMed International
Recordati Acquires HERBACOS-BOFARMA
Recordati Acquires Yeni Ilac
Tecnimede Acquires Majority Stake In Atlantic Pharma
Recordati Acquires Orphan Europe
Recordati Acquires Jaba Farmaceutica
Recordati Sells Minority Stake In Polfa Kutno To IVAX
Recordati Acquires Minority Stake In Polfa Kutno
Recordati Sells Sophartex To BTT Finances

List of Figures
Recordati S.p.A. – Pipeline by Indication, 2012
Recordati S.p.A. – Pipeline by Stage of Development, 2012
Recordati S.p.A. – Monotherapy Products in Pipeline, 2012
Recordati S.p.A. – Pipeline By Therapeutic Class, 2012
Recordati S.p.A. - Pipeline By Target, 2012
Recordati S.p.A. – Pipeline By Route of Administration, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos